Site of disease and opportunistic infection predict survival in HIV-assosiated truberculosis

AIDS

Volumn 11, Issue 4, 1997, Pages 455-460

  Whalen, Christopher ^a,e   Horsburgh Jr , C Robert ^b   Hom, David ^a   Lahart, Christopher ^c   Simberkoff, Michael ^d   Ellner, Jerrold ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV infection; Prognosis; Survival; Tuberculosis

Indexed keywords

CD4 ANTIGEN;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL; TUBERCULOSIS; TUBERCULOUS MENINGITIS;

EID: 0031048037     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199704000-00008     Document Type: Article

References (32)

1. Stoneburner R, Laroche E, Prevots R, et al.: Survival in a cohort of human immunodeficiency virus-infected tuberculosis patients in New York City. Arch Intern Med 1992, 152-2033-2037.
2. Perriens JH, Colebunders RL, Karahunga C, et al.: Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with 'standard' chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991, 144:750-755.
3. Nunn P, Brindle R, Carpenter L, et al.: Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (six-month) mortality. Am Rev Respir Dis 1992, 146:849-854.
4. Small PM, Schecter GT, Goodman PC, Sande MA, Chaisson RE, Hopewell PC: Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991, 324:289-294.
5. Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC: Tuberculosis in patients with the acquired immunodeficiency syndrome: clinical features, response to therapy, and survival. Am Rev Respir Dis 1987, 136:570-574.
6. Whalen C, Lahart C, Hom D, Simberkoff M, Ellner J, Horsburgh C: Accelerated clinical course of HIV infection after tuberculosis. Am J Respir Crit Care Med 1995, 151:129-135.
7. Wallis R, Helfand MS, Vjecha M, et al.: Immune activation allergic drug reactions, and mortality in HIV-associated pulmonary tuberculosis. Tubercle Lung Dis 1996 77:516-523.
8. Achak AN, Coulibaly D, Digbeu H, et al.: Response to treatment, mortality, and CD4 lymphocyte count in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet 1995, 345:607-610.
9. Shater RW, Small PM, Larkin C, et al.: Temporal trends and transmission patterns during the emergence of multi drug-resistant tuberculosis in New York City: a molecular epidemiologic assessment. J Infact Dis 1995, 171:170-176.
10. Fischl MA, Daikos GL, Uttamchandani RB, et al.: Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multi-drug-resistant bacilli. Ann Intern Med 1992, 117:184-190.
11. Centers for Disease Control: Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR 1986, 35:334-339.
12. Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 36 (suppl 1S):3S-15S.
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
14. Peto R, Pike MC, Armitage P, et al.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part 2: analysis and examples. Br J Cancer 1977, 35:1-39.
15. Harris EK, Albert A: Proportional hazards methods. Survivorship Analysis for Clinical Studies. New York: Marcel Dekker; 1991:79-125.
16. Selwyn PA, Hartel D, Lewis VA, et al.: A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320:545-550.
17. Reider HL, Cauthen GM, Bloch AB, et al.: Tuberculosis and acquired immunodeficiency syndrome - Florida. Arch Intern Med 1989, 149:1268-1273.
18. Okwera A, Whalen C, Byekwaso F, et al.: A randomized trial of thiacetazone- and rifampin-containing therapies for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994, 334:1323-1328.
19. Wenger JD, Whalen CC, Lederman MM, et al.: Prognostic factors in acquired immunodeficiency syndrome. J Gen Intern Med 1988, 3:464-470.
20. Theuer CP, Hopewell PC, Elias D, Schecter GF, Rutherford GW, Chaisson RE: Human immunodeficiency virus infection in tuberculosis patients. J Infact Dis 1990, 162:8-12.
21. Perronne C, Ghoubontni A, Leport C, Salmon-Ceron D, Bricaire F, Vilde JL: Should pulmonary tuberculosis be an AIDS-defining diagnosis in patients infected with HIV? Tubercle Lung Dis 1992, 73:39-44.
22. Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF: Relationship of the manifestations of tuberculosis to CD4 counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993, 148:1292-1297.
23. Mudaki Y, Perriens JH, St Louis ME, et al.: Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet 1993, 342:143-146.
24. Hanson DL, Horsburgh CR, Fann SA, Havlik JA, Thompson SE: Survival prognosis of HIV-infected patients. J Acquir Immune Defic Syndr 1993, 6:624-629.
25. Small PM, Moss A: Molecular epidemiology and the new tuberculosis. Infect Agents Dis 1993, 2:132-138.
26. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR: Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993, 328:527-532.
27. Pablos-Mendez A, Steding TR, Frieden TR: The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996, 276:1223-1228.
28. Whalen CC, Okwera A, Johnson J, et al.: Prognosis and survival in HIV-infected individuals with tuberculosis: a comparison of US and Ugandan cohorts [abstract]. Tubercle Lung Dis 1994, 75 (suppl 1):66A.
29. Shafer RW, Kim DS, Weiss JP, Quale JM: Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine 1991, 70:384-397.
30. Berenguer J, Moreno S, Laguna F, et al.: Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med 1992, 326:668-672.
31. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD: Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993, 342:268-272.
32. Whalen C, Nsubuga P, Johnson J, Mugerwa R, Ellner J: Preventive therapy for tuberculosis in HIV-infected Ugandans [abstract]. Tubercle Lung Dis 1995, 76 (suppl 2):135A.